Pseudopterygium: Unique Conjunctival Stricture Observed in Japanese White Rabbit

  • Katsuta Osamu
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.
  • Shinomiya Katsuhiko
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.
  • Mochizuki Takaharu
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.
  • Kikkawa Chinami
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.
  • Yoshimi Miwa
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.
  • Ikuse Toshimi
    Drug Safety and Pathology Group, Research & Development Center, Santen Pharmaceutical Co., Ltd.

この論文をさがす

説明

A unique conjunctive stricture was observed in the eye of a male 17-week-old Japanese White rabbit (Kbl:JW). The conjunctival membrane had proliferated centripetally and covered a large portion of the cornea. However, the membrane did not adhere to the cornea. Histopathologically, the inner epithelium of the conjunctival membrane appeared flattened, while the outer epithelium had become stratified and squamous. Goblet cells were observed on both sides of the epithelium. The lamina propria consisted of well-developed, vascularized collagen fiber. Myxoid change was seen near the tip of the membrane. In animals, these conjunctival membranes have been reported in a few dwarf rabbits, dogs and horses and have had various different terms applied to them due to their unknown etiology. Based on the conventions of human ophthalmology, such lesions should be regarded as pseudopterygia. Therefore, the present case was diagnosed as involving a pseudopterygium. The centripetal proliferation of the conjunctival membrane may be a characteristic finding in animal cases. Our goal is to encourage accumulation of such cases by researchers and practitioners working in the field of toxicology. <br>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (12)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ